FDA Approves Second Formulation of Humira Biosimilar Cyltezo
Drug Topics
MAY 1, 2024
According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.
Let's personalize your content